State Street’s Context Therapeutics CNTX Stock Holding History

State Street’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$783K	Buy	1,413,428 +1,179,921	+505%	+$2.39M	﹤0.01%	3503
2026 Q1	$612K	Buy	233,507 +67,900	+41%	+$159K	﹤0.01%	3606
2025 Q4	$243K	Buy	165,607 +13,000	+9%	+$15.2K	﹤0.01%	3856
2025 Q3	$148K	Hold	152,607	–	–	﹤0.01%	3979
2025 Q2	$100K	Hold	152,607	–	–	﹤0.01%	3973
2025 Q1	$93.4K	Hold	152,607	–	–	﹤0.01%	3985
2024 Q4	$160K	Buy	152,607 +40,700	+36%	+$70.4K	﹤0.01%	3897
2024 Q3	$219K	Buy	111,907 +19,800	+21%	+$43.9K	﹤0.01%	3804
2024 Q2	$185K	Buy	92,107 +59,200	+180%	+$102K	﹤0.01%	3847
2024 Q1	$45.4K	Hold	32,907	–	–	﹤0.01%	4179
2023 Q4	$37.2K	Hold	32,907	–	–	﹤0.01%	4253
2023 Q3	$49.7K	Hold	32,907	–	–	﹤0.01%	4291
2023 Q2	$52.7K	Hold	32,907	–	–	﹤0.01%	4406
2023 Q1	$18.5K	Hold	32,907	–	–	﹤0.01%	4690
2022 Q4	$21.7K	Hold	32,907	–	–	﹤0.01%	4720
2022 Q3	$37K	Buy	32,907 +14,607	+80%	+$26.3K	﹤0.01%	4717
2022 Q2	$39K	Buy	+18,300	New	+$34.3K	﹤0.01%	4769

Other funds holding CNTX

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street's CNTX Position: Q2 2026 in Review

State Street increased its Context Therapeutics (CNTX) stake by 505% in Q2 2026, buying an estimated $2.39M and bringing the position to 1,413,428 shares worth $783K. The position accounts for ﹤0.01% of the portfolio, ranked #3503.

State Street first reported a position in CNTX in Q2 2022 and has held it in 17 quarters since. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

State Street held 1,413,428 shares of Context Therapeutics worth $783K as of Q2 2026.
State Street bought 1,179,921 Context Therapeutics shares in Q2 2026, an estimated $2.39M.
Context Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3503 holding.
State Street first reported a position in Context Therapeutics in Q2 2022 and has held it in 17 quarters since.
43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.